TOKYO--(Business Wire / Korea Newswire)--Solasia Pharma K.K. (TOKYO:4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) officially announced today that an organoarsenic drug “DARVIAS® Injection 135mg” (SP-02, hereinafter DARVIAS®) has been launched today in Japan for use in relapsed or refractory Peripheral T-Cell Lymphoma. DARVIAS® will be commercialized by Nippon Kayaku Co., Ltd. (TOKYO:4272, Headquarters: Tokyo, Japan, President: Atsuhiro Wakumoto).
View source version on businesswire.com: https://www.businesswire.com/news/home/20220822005303/en/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220822005303/en/
Website: http://www.solasia.co.jp/en/
View Korean version of this release
Contact
Solasia Pharma K.K.
Toyokazu Ohata, Public Relations and Investor Relations
+81 3 5843 8046 (TOKYO)
info@solasia.co.jp
This news is a press release from the provider.
Korea Newswire is committed to verifying the transparency of providers and eliminating content errors.
You can receive press releases from this company or in industries of interest via email and RSS for free. Subscribe>
News provided bySolasia Pharma K.K.
Distribution Channel